HK$1.75
1.13%
Hong Kong, Oct 09, 02:46 pm HKT. Market open.
ISIN
BMG570071099
Symbol
2186

Luye Pharma Group Stock price

HK$1.77
-0.16 8.07% 1M
-1.11 38.50% 6M
-0.98 35.58% YTD
-1.81 50.56% 1Y
-1.70 48.99% 3Y
-2.16 54.97% 5Y
-3.66 67.44% 10Y
-4.94 73.66% 20Y
Hong Kong, Closing price Thu, Oct 08 2026
-0.03 1.40%
ISIN
BMG570071099
Symbol
2186
Industry

Is Luye Pharma Group a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,113 stocks worldwide.

Key metrics

Basic
Market capitalization
HK$7.0b
Enterprise Value
HK$9.1b
Net debt
HK$2.1b
Cash
HK$12.6b
Shares outstanding
4.0b
Valuation
P/E
9.8
P/S | estimate
1.0 | 1.0
EV/Sales | estimate
1.3 | 1.2
EV/FCF | ex SBC
- | -
P/B
0.4
Dividends
DPS
HK$0.00
Yield 1Y | 5Y
0.0% | 0.0%
Growth 1Y | 5Y
- | -100.0%
Payout 1Y | 3Y
0.0% | 0.0%
Increased
0 Years
Financials
Revenue | estimate
HK$7.2b | HK$7.4b
EBITDA
-
EBIT
HK$2.0b
Net Income
HK$815.3m
Free Cash Flow | ex SBC
- | -
Growth
Revenue | estimate
-0.6% | -0.4%
EBITDA
-
EBIT
20.5%
Net Income
75.4%
Free Cash Flow
-
Margin
Gross
63.8%
EBITDA
-
EBIT
27.6%
Net
11.4%
Free Cash Flow | ex SBC
- | -
Financial Health
Equity Ratio
49.0%
Return on Equity
3.9%
ROCE
7.6%
ROIC
5.8%
Debt/Equity
0.8
More
EPS
HK$0.2
FCF per Share
-
Short interest
-
Employees
5k
Rev per Employee
HK$1.4m

Luye Pharma Group Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Luye Pharma Group forecast:

6x Buy
75%
2x Hold
25%

Analyst Opinions

8 Analysts have issued a Luye Pharma Group forecast:

Buy
75%
Hold
25%

Financial data from Luye Pharma Group

Jun '26
+/-
%
7,176 7,176
1% 1%
100%
- Direct Costs 2,602 2,602
9% 9%
36%
4,575 4,575
5% 5%
64%
- Selling and Administrative Expenses 2,689 2,689
11% 11%
37%
- Research and Development Expense - -
-
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 1,979 1,979
21% 21%
28%
Net Profit 815 815
75% 75%
11%

In millions HKD.

Don't miss a Thing! We will send you all news about Luye Pharma Group directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Luye Pharma Group Ltd. is an investment holding company, which engages in the developing, producing, marketing, and selling of pharmaceutical products. The company employs 5,221 full-time employees The company went IPO on 2014-07-09. The firm operates four segments, including Oncology Drugs segment, Cardiovascular System Drugs segment, Alimentary Tract and Metabolism Drugs segment, and Central Nervous System Drugs segment. The Oncology Drugs segment provides Lipusu, Boyounuo, Baituowei, CMNa and Mimeixin and other drugs. The Cardiovascular System Drugs segment provides Xuezhikang, Oukai and Maitongna and other drugs. The Alimentary Tract and Metabolism Drugs segment provides Bei Xi and other drugs. The Central Nervous System Drugs segment provides Seroquel, Ruoxinlin, Rykindo, Meibirui and Jinyouping and other drugs.

Head office Bermuda
CEO Mr. Liu
Employees 5,221
Website www.luye.cn

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today